'anonymous' 'anonymous'
Sign in
Sign up

Your search

Filters

Previous project
Next project
We check with each center if new information is available.

2020-3448

Brain energy activation with ketones to prevent alzheimer's disease
Source : Import from center

clinicaltrials.gov reference: NCT04466735
Recruiment open
Last modification : 2025/06/02
Study type

Interventional


Target population

Medical condition (targeted specialty)

Data not available

Participants profils

Age limits
minimum: 55 years old maximum: 80 years old
Participants gender(s)

ALL

Source : Import from center

Selection criterias

Inclusion criteria

Inclusion Criteria:

* The participant must answer Yes to the question ''Do you think your memory is not as good as it was?''
* Have a MoCA Score between 20/30 and 26/30
* Have a QAF score of less than 9/30
* Understand, read and talk French
* Having good visual and hearing acuity

Exclusion Criteria:

* Major cognitive decline or neurodegenerative disease.
* Already consuming a daily medium chain triglyceride or ketone supplement.
* Soy, milk, gluten or allergy to the study product
* Controlled or uncontrolled diabetes
* Uncontrolled chronic disease
* Vitamin B12 deficit
* Clinical anomaly in the blood chemistry profile
* QSP-9 score over 19/27
* Taking an anti-cholinergic drugs
* Recent change in medication
* Active cancer in the last 2 years
* General anesthesia in the last 6 months
* history of alcohol abuse or dependence in the last 2 years
* Participation in other interventional or PET research project
* Unable to undergo an MRI or PET scan
* History of kidney stones or hypercalcemia
* History of cardiovascular events or insufficiency
* Renal failure and / or creatinine \<58 umol or\> 110 umol for men and \<46 umol or\> 92 umol for women or if the GFR (glomerular filtration rate) \<60 ml / min / 1.73 m2
* Chronic disease of the digestive system or intestinal malabsorption (celiac disease, chronic pancreatitis, Crohn's disease, etc.)
* Body mass index \<20 or voluntary weight loss of more than 5% in the last 6 months.

Source : Import from center

Proposed Therapy or Intervention

Cohorts
Name Medical condition Treatment Recruitment status
Active group Participants will be on the active intervention for 6 months Data not available
  • Unknown
  • Placebo Group Participants will be on the placebo intervention for 6 months Data not available
  • Unknown
  • Open phase on active product At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months. Data not available
  • Unknown
  • Active group
    Recruitment status
    unknown
    Placebo Group
    Recruitment status
    unknown
    Open phase on active product
    Recruitment status
    unknown
    Current data since : June 02, 2025 20:00

    Study description

    Study summary

    A six month randomized controlled intervention with an exogenous ketone salt (EKS) supplement in mild cognitive impairment. Participants will receive 15 g of the supplement twice daily (equivalent to 24 g/day of EKS). Outcomes: brain energy metabolism, cognition, plasma biomarkers, brain imaging (volumetric, functional, structural) and quality of life will be analyzed before and after the intervention.

    Source : Import from center

    Locations

    Participating centers

      1 centers
    • CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE * **

      Sherbrooke

      QUÉBEC, CANADA

      Local recruitment
      Recruiting status: OPEN
      Contact details for recruitment
      Local project contacts
      researchers:
      • CunnaneS

      co-researchers:
      • LepageM

      • WhittingstallK

      • TurcotteÉ

      • BoctiC

      • FülöpT

      • DescoteauxM

      click here for more information about this center
      Cohorts
      Centre hospitalier universitaire de Sherbrooke
      Data not available
      Current data since : February 04, 2026 12:04

    Last modification : June 02, 2025
    Current data since : 05 May 22:47
    Data source : clinicaltrials.gov
    Nagano reference: 2020-3448
    clinicaltrials.gov reference: NCT04466735